课题基金 / 基金详情

structural characterization of iron uptake from human transferrin

structural characterization of iron uptake from human transferrin
人转铁蛋白吸收铁的结构特征
批准号:
8553451
负责人:
Susan Buchanan
金额:
$92.18万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Susan Buchanan的其他基金

相似基金

相关文献

中文摘要
翻译
2011年完成了以下工作: 细菌和人蛋白的表达、纯化及其复合体的形成 我们在2007年解决了全长脱脂人类转铁蛋白的结构,并发表了这一结构(Wally等人,J.Biol。化学。2007)。在过去的一年里,我们利用这些信息对下面描述的TbpA-HTF的复杂结构进行了定相,同时我们解决了一个分辨率高得多的apo HTF C瓣结构,分辨率达到1.7。 我们建立了TbpA的表达系统,可生产0.2-0.4 mg/L的纯化蛋白。将含有TbpA基因和N-末端组氨酸标签的质粒转化到大肠杆菌的大规模制备(27L)中,用低水平的IPTG诱导过夜,然后收获。我们最近通过定向突变C-末端β链来提高表达产量,使新合成的蛋白质能够更有效地被大肠杆菌膜插入机械处理。 我们建立了TbpB的表达系统,可生产7-8 mg/L的纯化蛋白。将含有TbpB基因(缺乏N端膜锚定的可溶构建体)以及N端组蛋白标签和裂解位点的质粒转化到中等规模的大肠杆菌(4L)中,用高水平的IPTG诱导几小时,然后收获。然后细胞被裂解,膜通过超速离心法分离,可溶部分在镍-NTA柱上运行。然后,镍洗脱液进一步纯化,并可与商业上可获得的纯化的铁结合的人血清转铁蛋白结合。今年我们将TbpB的结构解析为2.65分辨率。 用提纯的TbpB只与全息HTF结合,制备了TbpB-Holo HTF络合物,并用小角X射线散射对其进行了表征。因为我们有这两个蛋白质组分的结构,所以我们能够从结构上表征这个复合体,尽管我们还不能使它结晶。 我们最近获得了TbpA+HTF(共180 kDa)的晶体,它能将X射线衍射到2.65分辨率。2010年8月,通过使用我们的HTF坐标(Wally等人,JBC 2007)和各种TonB依赖的转运蛋白模型进行分子置换,解决了该结构。这种结构是外膜蛋白与其全长宿主靶标(例证宿主相互作用)形成复合体的第一个结构,它告诉我们人转铁蛋白的特异性,这种相互作用中涉及的残基,可变和保守的表位位于细胞外表面(对疫苗设计有用),如何从HTF中提取铁,以及它如何通过外膜运输。当TbpA与HTF结合时,它通过由81个TbpA残基和67个HTF残基组成的广泛界面隔离埋藏表面的2500 2。这座建筑是一项里程碑式的成就,耗时12年建成。 最近,我们首次制备了TbpA-TbpB与全息人转铁蛋白(HTF)的体外络合物,并用负染色单粒子电子显微镜对其进行了表征。从TbpA-HTF晶体结构和TbpB-HTF SAXS结构出发,建立了适合于EM三维重建的三元络合物模型。从所有这些数据中,我们现在了解了识别的特异性,并已经设计出可以阻断TbpA-转铁蛋白相互作用的抗体。由于TbpA和TbpB在所有临床分离株中都存在,因此它们是重要的治疗靶点。这是最大的外膜蛋白复合体之一,具有高分辨率,并具有直接翻译应用。描述结晶学、SAXS、EM和功能分析的手稿最近提交给了《自然》杂志。 2012年更新:这项工作以文章形式发表在2012年2月的《自然》杂志上。我们现在已经对奈瑟氏菌的铁进口途径提供了完整的结构描述,并建立了几个可检验的铁提取和进口假说。这项工作已经被认为是一篇里程碑式的论文,对该领域产生了重大影响,并改变了内瑟利亚未来实验的进程。
英文摘要
The following work was accomplished in 2011: Expression, Purification and Complex Formation of Bacterial and Human Proteins We solved the structure of full-length, apo human transferrin in 2007 and published this structure (Wally et al., J. Biol. Chem. 2007). Thispast year we used the information to phase a complex structure for TbpA-hTf described below, and at the same time we solved a much higher resolution structure of apo hTf C-lobe to 1.7 resolution. We developed an expression system for TbpA that is capable of producing 0.2-0.4 mg/L of purified protein. A large scale preparation (27L) of E. coli transformed with a plasmid containing the gene for TbpA as well as an N-terminal His-Tag is grown and induced with low level IPTG overnight and then harvested. We recently improved expression yields through targeted mutagenesis of the C-terminal beta strand, allowing the newly synthesized protein to be more efficiently processed by the E. coli membrane insertion machinery. We developed expression system for TbpB that is capable of producing 7-8 mg/L of purified protein. A medium scale preparation (4L) of E. coli transformed with a plasmid containing the gene for TbpB (a soluble construct lacking the N-terminal membrane anchor) as well as an N-terminal His-Tag and a cleavage site are grown and induced with high level IPTG for a few hours and then harvested. The cells are then lysed and membranes are separated via ultracentrifugation, and the soluble fraction is run over a Nickel-NTA column. The nickel eluate is then further purified and can be bound to purified commercially available iron-bound human serum transferrin. We solved the structure of TbpB to 2.65 resolution this year. Using our purified TbpB, which only binds holo hTf, we made a TbpB-holo hTf complex and characterized it using small angle X-ray scattering. Since we have structures of the two protein components, we were able to structurally characterize the complex, even though we have not been able to crystallize it. We recently obtained crystals of TbpA+hTf (180 kDa total) that diffract X-rays to 2.65 resolution. The structure was solved in August 2010 by molecular replacement using our hTf coordinates (Wally et al., JBC 2007) and various TonB-dependent transporter models. This structure, the first of an outer membrane protein in complex with its full-length host target (exemplifying host pathogen interactions), tells us about the specificity for human transferrin, the residues involved in this interaction, where variable and conserved epitopes are located on the extracellular surface (useful for vaccine design), how iron is extracted from hTf, and how it is transported across the outer membrane. When TbpA binds hTf, it sequesters 2500 2 of buried surface through an extensive interface consisting of 81 TbpA residues and 67 hTf residues. This structure is a landmark achievement, taking 12 years to complete. Recently, we made the first ever in vitro complex of TbpA-TbpB bound to holo human transferrin (hTf) and this triple complex was characterized by negative stain single particle electron microscopy. From the TbpA-hTf crystal structure and the TbpB-hTf SAXS structure, we made a model for the triple complex which fits beautifully into the EM 3D reconstruction. From all of these data, we now understand the specificity of recognition and have already designed antibodies that can block the TbpA-transferrin interaction. Since TbpA and TbpB are present in all clinical isolates, they represent important therapeutic targets. This is one of the largest outer membrane protein complexes characterized at high resolution and it has direct translational applications. A manuscript describing the crystallography, SAXS, EM, and functional analysis was recently submitted to Nature. Update for 2012: This work was published as an article in Nature in February 2012. We have now provided a complete structural description of the iron import pathway in Neisseria and established several testable hypotheses for iron extraction and import. This work is already regarded as a landmark paper that has significantly impacted the field and changed the course of future experiments in Neisseria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural characterization of OM proteins from Gram-negative pathogens
structural characterization of iron uptake from human transferrin
Structural characterization of OM proteins from Gram-negative pathogens
Structural characterization of outer membrane proteins from Yersinia pestis
海外基金